Divalent Chalcogen Or Acyclic Nitrogen Double Bonded At 2-position, Or Tautomeric Equivalent Patents (Class 514/392)
  • Patent number: 10821097
    Abstract: The present invention relates to the use of DBH inhibitors (e.g., disulfiram and Nepicastat), and pharmaceutical compositions thereof, for treating subjects with certain types of memory loss, for instance memory loss associated with a neurodegenerative disease, disorder, or condition, such as Alzheimer's Disease.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: November 3, 2020
    Assignee: Brandeis University
    Inventor: John Lisman
  • Patent number: 10130609
    Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 20, 2018
    Assignees: UNIVERSITY HEALTH NETWORK, CANADIAN BLOOD SERVICES
    Inventors: Donald R. Branch, Lakshmi P. Kotra
  • Patent number: 10064944
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 4, 2018
    Assignee: NOVALIQ GMBH
    Inventor: Clive G. Wilson
  • Patent number: 9642819
    Abstract: The present invention is directed to a method for the treatment of an inflammatory disorder in a mammal, said method comprising administering to a mammal in need of such treatment a therapeutically effective amount of (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ((R)-DOI) in a pharmaceutically acceptable carrier or salt thereof, wherein said inflammatory disorder is associated with a disease selected from asthma, rheumatoid arthritis, irritable bowel syndrome, and Crohn's disease.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: May 9, 2017
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL
    Inventors: Charles D. Nichols, Bangning Yu
  • Patent number: 9248135
    Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: February 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Rhett M. Schiffman, June Chen
  • Patent number: 9226921
    Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia or so on represented by the formula (I):
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: January 5, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takahiko Taniguchi, Masato Yoshikawa, Kasei Miura, Tomoaki Hasui, Eiji Honda, Keisuke Imamura, Makoto Kamata, John F. Quinn, Joseph Raker, Fatoumata Camara, Yi Wang
  • Patent number: 9196844
    Abstract: A novel method includes a synthetic pathway in which ?-diketone and a 1-(haloaryl)ethane-1,2-diamine derivative are cyclized to each other to form a 2-(haloaryl)pyrazine derivative. Further, a 2-arylpyrazine derivative having an aryl group or a heteroaryl group as a substituent is synthesized by coupling the 2-(haloaryl)pyrazine derivative obtained by the above synthetic pathway and an arylboronic acid or a heteroarylboronic acid. The 2-arylpyrazine derivative obtained by the novel method is useful for a light-emitting element, a light-emitting device, an electronic device, or a lighting device with high emission efficiency.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: November 24, 2015
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hideko Inoue, Tomoya Yamaguchi, Yasushi Kitano, Hiromi Seo, Satoshi Seo
  • Patent number: 9145395
    Abstract: Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: September 29, 2015
    Assignee: North Carolina State University
    Inventors: Christian Melander, Steven A. Rogers, Robert W. Huigens, III, Catherine S. Reed
  • Patent number: 9034888
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R7, R6, R7, R8, R9, A, X and Y as defined herein are provided as useful for the treatment of cancer or for the manufacture of anti-cancer agents.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: May 19, 2015
    Assignee: Universite Laval
    Inventors: René C. Gaudreault, Sébastien Fortin
  • Publication number: 20150133516
    Abstract: The present invention provides compositions and methods of using ?2 adrenergic receptor agonists as treatments for ADHD. The ?2 adrenergic receptor agonist for use with these methods is a benzimidazole derivative, and may be specifically N-(4,5-Dihydro-1H-imidazol-2-yl)-7-cyano-4-methyl-1H-benzimidazol-5-amine acetate. Formulations and routes of administration are also described.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 14, 2015
    Inventors: Brian K. Adams, Ed Schutter
  • Publication number: 20150133422
    Abstract: The present invention embodiments relate to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates in certain embodiments to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates in certain embodiments to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates in certain embodiments to a process for manufacturing compounds of Formula I.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 14, 2015
    Inventors: Stefano Crosignani, Sandra Cauwenberghs, Frederik Deroose
  • Patent number: 9018206
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 28, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
  • Publication number: 20150111882
    Abstract: The present invention provide compounds of Formula (I) used as BACE inhibitors for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 23, 2015
    Applicant: Ares Trading S.A.
    Inventors: Anna Quattropani, Dominique Swinnen
  • Publication number: 20150105354
    Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(?S)—, —S(O)—, —S(O)2—, —C(?O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(?N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(?O)— or —C(?NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(?NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Applicants: MERCK SHARP & DOHME CORP., PHARMACOPEIA, LLC
    Inventors: Zhaoning Zhu, Brian McKittrick, Zhong-Yue Sun, Yuanzan C. Ye, Johannes H. Voigt, Corey Strickland, Elizabeth M. Smith, Andrew W. Stamford, William J. Greenlee, Robert D. Mazzola, JR., John Caldwell, Jared N. Cumming, Lingyan Wang, Yusheng Wu, Ulrich Iserloh, Tao Guo, Thuy X.H. Le, Kurt W. Saionz, Suresh D. Babu, Rachael C. Hunter
  • Publication number: 20150099786
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 9, 2015
    Inventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
  • Patent number: 8992891
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: March 31, 2015
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Oxana Guerassimenko, Serguei Nabirochkin
  • Publication number: 20150073027
    Abstract: Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a trimethylamine absorber in an amount sufficient to prevent the detection of any trimethylamine odor by the human nose. A method is further provided for ameliorating the methylamine odor associated with an aqueous ergothioneine-containing preparation after it has developed a fishy trimethylamine odor.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Applicant: ELC Management LLC
    Inventor: Daniel B. Yarosh
  • Publication number: 20150065561
    Abstract: The present invention is based, in part, on our studies of molecular pathways that include the deubiquitinase CYLD. Accordingly, the present invention features, inter alia, nucleic acid constructs that express CYLD or a biologically active variant thereof (e.g., a variant including the catalytic domain), nucleic acids that inhibit the expression of a negative regulator of CYLD (e.g., PDE4B or LNK2), nucleic acids that modulate the expression of downstream CYLD targets (e.g., Akt, by inhibiting or promoting the expression of the downstream target), compositions including one or more of these types of constructs (e.g., pharmaceutical compositions), kits including one or more of the compositions described herein and instructions for use, screening methods to identify therapeutic agents {e.g., anti-inflammatory agents) that upregulate CYLD, downregulate a negative regulatory of CYLD, or modulate (e.g., inhibit) a downstream CYLD target (e.g.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 5, 2015
    Applicant: Georgia State University Research Foundation, Inc.
    Inventor: Jian-Dong Li
  • Patent number: 8927029
    Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: January 6, 2015
    Assignee: North Carolina State University
    Inventors: Christian Melander, John Cavanagh, David Ritchie, Robert W. Huigens, III, T. Eric Ballard, Justin J. Richards, Thomas W. Lindsey, Jonathan S. Lindsey
  • Publication number: 20150005260
    Abstract: The present invention relates to methods and kits for detecting diastolic dysfunction in subjects without clinical signs of heart failure.
    Type: Application
    Filed: January 2, 2013
    Publication date: January 1, 2015
    Inventors: Faiez Zannad, Patrick Rossignol
  • Publication number: 20140363479
    Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 11, 2014
    Inventors: Thomas Julius BORODY, Soledad CARSULA
  • Publication number: 20140356290
    Abstract: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Inventors: Neil Barman, Howard Levin, Paul Sobotka, Mark Gelfand
  • Patent number: 8901160
    Abstract: A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): wherein n is an integer of 1 to 3, R1 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, X is —CH2— or a group represented by —N(R2)—, and R2 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, or a salt thereof.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: December 2, 2014
    Assignee: Shiseido Company, Ltd.
    Inventors: Shunsuke Iriyama, Hirotada Fukunishi, Masaru Suetsugu, Satoshi Amano
  • Publication number: 20140323519
    Abstract: This invention relates to novel heterocyclic compounds that are useful for treating cancer and other cellular proliferative diseases and/or disorders associated with B-Raf activity. The compounds of the invention may be illustrated by the Formula (I).
    Type: Application
    Filed: April 20, 2012
    Publication date: October 30, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: M. Arshad Siddiqui, Lianyun Zhao, Amit K. Mandal
  • Publication number: 20140314787
    Abstract: The present application provides a method for treating a neurodegenerative disease in a subject characterised in that the endoplasmic reticulum protein retrotranslocation machinery and/or VCP is modulated by administering to said subject a therapeutically effective amount of a modulator of said endoplasmic reticulum protein retrotranslocation machinery and/or of VCP.
    Type: Application
    Filed: November 7, 2012
    Publication date: October 23, 2014
    Inventors: Pico Caroni, Francesco Roselli
  • Publication number: 20140315968
    Abstract: Compounds of formula (I) wherein R1, R4, R8, X and Y as defined herein are provided as useful for the inhibition of certain types of cancer cells, amongst others, breast cancer cells, or for the manufacture of anti-cancer agents.
    Type: Application
    Filed: August 10, 2012
    Publication date: October 23, 2014
    Applicant: UNIVERSITE LAVAL
    Inventors: Rene C.-Gaudreault, Sebastien Fortin
  • Publication number: 20140309240
    Abstract: The invention provides novel, water-soluble 2-aminoimidazoline derivatives having general Formula (I) as well as some precursors of Formula (I), which are very potent inducers of G2/M cell cycle arrest. In treated tumor cells, compounds of Formula (I) give gene expression profile distinct from known antimitotic agents. The invention also provides methods for preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools.
    Type: Application
    Filed: April 9, 2014
    Publication date: October 16, 2014
    Inventors: Stanislaw Wieslaw Pikul, Wieslaw Marek Cholody
  • Publication number: 20140309259
    Abstract: The invention provides novel, water-soluble 2-aminoimidazoline derivatives having general Formula (I) as well as some precursors of Formula (I), which are very potent inducers of G2/M cell cycle arrest. In treated tumor cells, compounds of Formula (I) give gene expression profile distinct from known antimitotic agents. The invention also provides methods for preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 16, 2014
    Inventors: Stanislaw Wieslaw Pikul, Wieslaw Marek Cholody
  • Patent number: 8846739
    Abstract: TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: September 30, 2014
    Assignee: Exelixis Patent Company LLC
    Inventors: Venkataiah Bollu, Brant Clayton Boren, Jackaline Dalgard Julien, Brenton T. Flatt, Nadia Haq, Sarah Hudson, Raju Mohan, Michael Morrissey, Benjamin Pratt
  • Patent number: 8846746
    Abstract: The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: September 30, 2014
    Assignee: Japan Tobacco Inc.
    Inventors: Tomoya Miura, Yosuke Ogoshi, Kazuhito Ueyama, Dai Motoda, Toshihiko Iwayama, Koichi Suzawa, Hironobu Nagamori, Hiroshi Ueno, Akihiko Takahashi, Kazuyuki Sugimoto
  • Patent number: 8835426
    Abstract: This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: September 16, 2014
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Gerard McGeehan, Suresh B. Singh, Colin M. Tice, Yuanjie Ye, Wei Zhao
  • Publication number: 20140235599
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signalling and thyroid hormone pathway in a subject.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 21, 2014
    Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, OXANA GUERASSIMENKO
  • Publication number: 20140235685
    Abstract: The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
    Type: Application
    Filed: March 25, 2014
    Publication date: August 21, 2014
    Applicant: Allergan, Inc.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • Patent number: 8802128
    Abstract: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 12, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Scott M. Whitcup
  • Patent number: 8802866
    Abstract: Compounds of the formula (I), in which X1, X2, L, Y, R2, R3, R4, R5, R6, R7, R8, R9, R10 have the meanings indicated in claim 1, are PI3K inhibitors and can be employed, inter alia, for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumors.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Patent GmbH
    Inventors: Ulrich Emde, Hans Peter Buchstaller, Markus Klein, Christina Esdar, Joerg Bomke
  • Publication number: 20140221383
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 7, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Hallet, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith, Julianne A. Hunt, Adrian A. Dowst, Yi-Heng Chen, Hong Li
  • Publication number: 20140199362
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a fiber at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate fiber formulations are provided within biodegradable polymers, this pain relief can be continued for at least three days.
    Type: Application
    Filed: January 15, 2013
    Publication date: July 17, 2014
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: Danielle L. Clay
  • Publication number: 20140171363
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Gregory Raymond BEBERNITZ, Kevin CLAIRMONT, Scott Louis COHEN, Robert Edson DAMON, II, Robert Francis DAY, Stephanie Kay DODD, Christoph GAUL, Hatice Belgin GULGEZE EFTHYMIOU, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Kai LIN, Justin Yik Ching MAO, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, SU Liansheng
  • Publication number: 20140171490
    Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.
    Type: Application
    Filed: August 9, 2013
    Publication date: June 19, 2014
    Applicant: PHARMALINGT INC.
    Inventors: Yossi Gross, Rafi Herzog, Steven B. Koevary
  • Publication number: 20140161917
    Abstract: Methods of using nesprin-2 modulators to impart anti-aging benefits to the skin and/or improve skin conditions.
    Type: Application
    Filed: October 30, 2013
    Publication date: June 12, 2014
    Applicant: Avon Products, Inc.
    Inventors: John W. Lyga, Ying Chen, Qian Zheng, Uma Santhanam
  • Patent number: 8748467
    Abstract: The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: June 10, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Karthigeyan Nanjan, Fadil Al Alawi, Paul Chambers, Kate Hill
  • Publication number: 20140148438
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 29, 2014
    Inventor: Michael Farber
  • Publication number: 20140142124
    Abstract: A composition comprising at least one physiologically tolerated film-forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing. The composition is suitable for treatment of androgenic alopecia or hirsutism, that is, for avoiding undesirable hair growth, and for treatment of seborrhea and acne, and can furthermore be employed in cosmetics.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 22, 2014
    Inventors: Karl Theodor Kraemer, Manfred Bohn
  • Patent number: 8729112
    Abstract: This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: May 20, 2014
    Assignee: Novabay Pharmaceuticals, Inc.
    Inventors: Timothy Shiau, Charles Francavilla, Eddy Low, Eric Douglas Turtle, Donogh John Roger O'Mahony, Rakesh K. Jain
  • Publication number: 20140099336
    Abstract: Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 10, 2014
    Applicant: Biotie Therapies, Inc.
    Inventors: Tom Woiwode, Mark Moran, Lesley Pickford
  • Publication number: 20140094495
    Abstract: This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.
    Type: Application
    Filed: November 14, 2012
    Publication date: April 3, 2014
    Applicant: NovaBay Pharmaceuticals, Inc.
    Inventors: Timothy K. Shiau, Charles Francavilla, Eddy Low, Eric Douglas Turtle, Donogh John Roger O'Mahony, Rakesh K. Jain
  • Publication number: 20140080878
    Abstract: A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): wherein n is an integer of 1 to 3, R1 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, X is —CH2— or a group represented by —N(R2)—, and R2 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, or a salt thereof.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 20, 2014
    Applicant: Shiseido Company, Ltd.
    Inventors: Shunsuke Iriyama, Hirotada Fukunishi, Masaru Suetsugu, Satoshi Amano
  • Publication number: 20140079808
    Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: North Carolina State University
    Inventors: Christian Melander, John Cavanagh, David Ritchie, Robert W. Huigens, III, T. Eric Ballard, Justin J. Richards, Thomas W. Lindsey, Jonathan S. Lindsey
  • Publication number: 20140080896
    Abstract: This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a small molecule selected from the compounds shown in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicant: The Regents of the University of california
    Inventors: Stanley F. Nelson, Carrie Miceli, Miriana Moran
  • Publication number: 20140073574
    Abstract: A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 13, 2014
    Inventors: Robert L. Roden, Richard J. Gorczynski, Michael J. Gerber